Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 9, 2014, Pages 5872-5879

  Jin, Ziliang ^a   Jiang, Weihua ^a   Jiao, Feng ^a   Guo, Zhen ^a   Hu, Hai ^a   Wang, Lei ^a   Wang, Liwei ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Gastric cancer; Histone deacetylase 10; Immunohistochemistry; Prognosis

Indexed keywords

HDAC10 PROTEIN, HUMAN; HISTONE DEACETYLASE; TUMOR MARKER;

ADULT; AGED; CANCER GRADING; CANCER STAGING; CHI SQUARE DISTRIBUTION; DOWN REGULATION; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEX DIFFERENCE; STOMACH TUMOR; TIME FACTOR; TISSUE MICROARRAY; TUMOR INVASION; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CHI-SQUARE DISTRIBUTION; DOWN-REGULATION; FEMALE; HISTONE DEACETYLASES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX FACTORS; STOMACH NEOPLASMS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR BURDEN;

EID: 84911496124     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Lee JH, Kim KM, Cheong JH, Noh SH. Current management and future strategies of gastric cancer. Yonsei Med J 2012; 53: 248-257.
3. Piazuelo MB, Correa P. Gastric cancer: Overview. Colomb Med (Cali) 2013; 44: 192-201.
4. Thiel A, Ristimaki A. Gastric cancer: basic aspects. Helicobacter 2012; 17 Suppl 1: 26-29.
5. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol 2013; 10: 643-655.
6. Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, Longacre M. Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci 2013; 14: 21087-21113.
7. Lai IL, Lin TP, Yao YL, Lin CY, Hsieh MJ, Yang WM. Histone deacetylase 10 relieves repression on the melanogenic program by maintaining the deacetylation status of repressors. J Biol Chem 2010; 285: 7187-7196.
8. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006; 281: 13548-13558.
9. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004; 112: 26-32.
10. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001; 92: 1300-1304.
11. CH SLaW. International Union Against Cancer. TNM Classification of Malignant Tumors. 6th ed. New York: John Wiley-Liss; 2002.
12. Kumar P, Tripathi S, Pandey KN. Histone Deacetylase Inhibitors Modulate the Transcriptional Regulation of Guanylyl Cyclase/Natriuretic Peptide Receptor-A Gene: Interactive roles of modified histones, histone acetyltransferase, p300, AND Sp1. J Biol Chem 2014; 289: 6991-7002.
13. Shimazu T, Horinouchi S, Yoshida M. Multiple histone deacetylases and the CREB-binding protein regulate pre-mRNA 3'-end processing. J Biol Chem 2007; 282: 4470-4478.
14. Tong JJ, Liu J, Bertos NR, Yang XJ. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res 2002; 30: 1114-1123.
15. Song C, Zhu S, Wu C, Kang J. Histone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase (MMP) 2 and 9 expression. J Biol Chem 2013; 288: 28021-28033.
16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
17. Zheng L, Wang L, Ajani J, Xie K. Molecular basis of gastric cancer development and progression. Gastric Cancer 2004; 7: 61-77.
18. Gargalionis AN, Piperi C, Adamopoulos C, Papavassiliou AG. Histone modifications as a pathogenic mechanism of colorectal tumorigenesis. Int J Biochem Cell Biol 2012; 44: 1276-1289.
19. Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012; 6: 579-589.
20. Yasui W, Oue N, Ono S, Mitani Y, Ito R, Nakayama H. Histone acetylation and gastrointestinal carcinogenesis. Ann N Y Acad Sci 2003; 983: 220-231.
21. Feng L, Pan M, Sun J, Lu H, Shen Q, Zhang S, Jiang T, Liu L, Jin W, Chen Y, Wang X, Jin H. Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells. J Mol Med (Berl) 2013; 91: 49-58.
22. Muller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, Winzer KJ, Dietel M, Weichert W, Denkert C. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 2013; 13: 215.
23. Du X, Zhao H, Zang L, Song N, Yang T, Dong R, Yin J, Wang C, Lu J. Overexpression of histone deacetylase 2 predicts unfavorable prognosis in human gallbladder carcinoma. Pathol Oncol Res 2013; 19: 397-403.
24. Wisnieski F, Calcagno DQ, Leal MF, Chen ES, Gigek CO, Santos LC, Pontes TB, Rasmussen LT, Payao SL, Assumpcao PP, Lourenco LG, Demachki S, Artigiani R, Burbano RR, Cardoso Smith M. Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A. Tumour Biol 2014; 35: 6373-81.
25. Zhang X, Yashiro M, Ren J, Hirakawa K. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 2006; 16: 563-568.
26. Lin KT, Wang YW, Chen CT, Ho CM, Su WH, Jou YS. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy. Clin Cancer Res 2012; 18: 4691-4701.